Bristol Myers Squibb stock pre-market at EUR 53.12: plus 0.42 percent
Published on 10/07/2026 at 08:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock was at EUR 53.12 pre-market at 8:10 a.m. CEST on October 7, 2026, according to Lang & Schwarz. The price was up 0.42 percent versus the EUR 52.90 prior close at Lang & Schwarz on October 6, 2026.
Pre-market trading
Lang & Schwarz showed a bid of EUR 52.93 and an ask of EUR 53.31. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Prior close
The October 6, 2026, prior close at Lang & Schwarz was EUR 52.90. The current pre-market indication and the prior close are both euro quotes from Lang & Schwarz.
CAMZYOS indication expanded
In a September 30, 2026, release, Bristol Myers Squibb said the U.S. Food and Drug Administration approved CAMZYOS for symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kilograms. The company said the approval was based on results from the Phase 3 SCOUT-HCM trial.
Third-quarter results scheduled
Bristol Myers Squibb said in a September 18, 2026, release that it will report third-quarter 2026 results on October 29, 2026. The company said executives will review the results during a conference call beginning at 8:00 a.m. Eastern Time; the release was published by Bristol Myers Squibb.
